LRRC8C-DT: A Potential Drug Target and Biomarker (G400761)

Target Name: LRRC8C-DT

NCBI ID: G400761

LRRC8C-DT

Other Name(s): LRRC8C divergent transcript

LRRC8C-DT: A Potential Drug Target and Biomarker

Introduction

The long non-coding RNA (lncRNA) landscape has experienced a surge in the recent years, as researchers have identified numerous functional lncRNAs that play critical roles in various cellular processes. One of these lncRNAs is the long non-coding RNA (lncRNA) LRRC8C (Long non-coding RNA LRRC8C), which has been shown to play a significant role in regulating gene expression and has been associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In this article, we will discuss the LRRC8C-DT gene, which is a potential drug target and biomarker for various diseases. We will review the current research on LRRC8C and its potential therapeutic applications, as well as its potential as a biomarker for disease diagnosis and monitoring.

Current Research on LRRC8C

The LRRC8C gene was first identified in the human transcriptome using RNA-seq technology. The RNA-seq data revealed that LRRC8C is a highly expressed lncRNA with a highly maintained gene expression level in various tissues and cells, including brain, heart, and various cancer types.

Subsequent studies have shown that LRRC8C is involved in various cellular processes, including cell adhesion, migration, and invasion. It has also been shown to play a role in regulating cell cycle progression and apoptosis. In addition, LRRC8C has been linked to various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

LRRC8C as a Potential Drug Target

The potential drug target for LRRC8C is based on its involvement in various cellular processes that are associated with disease. One of the primary targets for LRRC8C is the regulation of cell adhesion, which is critical for the maintenance of tissue structure and has been implicated in various diseases, including cancer.

Research has shown that LRRC8C is involved in the regulation of cell adhesion by activating the Focal Adhesion Protein (FAP) signaling pathway. This pathway is known to play a role in the regulation of cell migration and the development of cancer. By activating FAP signaling, LRRC8C has been shown to promote the formation of cancer cell-stromal cell adhesion, which is critical for the development and progression of cancer.

Additionally, LRRC8C has also been shown to play a role in the regulation of cell apoptosis, which is the process by which cells undergo programmed cell death. This is critical for the regulation of tissue homeostasis and has been implicated in various diseases, including cancer.

LRRC8C as a Biomarker

LRRC8C has also been shown to be a potential biomarker for various diseases, including cancer. The high expression level of LRRC8C in various tissues and cells, as well as its involvement in the regulation of cellular processes that are associated with disease, makes it an attractive candidate for use as a biomarker.

Studies have shown that LRRC8C can be used as a biomarker for various diseases, including cancer. For example, research has shown that LRRC8C is highly expressed in various types of cancer, including breast, lung, and ovarian cancer. Additionally, studies have shown that LRRC8C can be used as a biomarker for disease diagnosis, as LRRC8C levels have been shown to be associated with the severity of various diseases, including cancer.

Conclusion

LRRC8C is a promising candidate for drug targeting and biomarker for various diseases. Its involvement in the regulation of cell adhesion, cell apoptosis, and

Protein Name: LRRC8C Divergent Transcript

The "LRRC8C-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRC8C-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets